Compare Johnson & Johnson (JNJ) vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value (VIST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value trades at $66.26 (market cap $7.43B). The key difference: Johnson & Johnson is far larger — about 83.2× Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value's market cap, and Johnson & Johnson pays a 2.09% dividend while Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value for 1 Days on average.
| JNJ | VIST | |
|---|---|---|
Market Cap | $618.09B | $7.43B |
Volume | 6,050,983 | 875,552 |
Sector | Health | Energy |
52-Week High | $278.43 | $79.25 |
52-Week Low | $186.00 | $35.02 |
Typical Hold Time | 129 Days | 1 Days |
Enterprise Value | $646.37B | $10.58B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value
Vista Energy is an independent oil and gas company focused on exploration, development, and production in Latin America. Its operations are centered on the Vaca Muerta formation in Argentina.
Read more on VIST →
